Soaring Ambitions, Chasing Dreams: Fresh Wind Biotechnologies' TIL Therapy Enters Phase I Clinical Trial

VCBeat learned at the first time that DISCOVERY TO CURE announced its immune cell TIL therapy has been approved by the U.S. FDA to enter Phase I clinical trials.DISCOVERY TO CURE, founded by scientist-entrepreneur Dr. Fuli Yu in 2020, has already entered the registered clinical stage within just over a year. This time, DISCOVERY TO CURE is collaborating with top-tier U.S. cancer treatment centers and leading clinical principal investigators (PIs) to advance the FDA Phase I clinical trial of TIL immunotherapy for solid tumor patients.

DISCOVERY TO CURE fully leverages the revolutionary role of multi-omics big data and artificial intelligence in today's era of precision medicine (paradigm shift), closely aligns with the characteristics of TIL cell therapy, optimizes the underlying R&D of “NextGenTILTM,” enhances preparation processes, and rapidly advances clinical trials.

DISCOVERY TO CURE was founded in early 2020 by entrepreneur and scientist Dr. Fuli Yu. It aims to develop the clinical application of TIL therapy for treating and curing solid tumor patients and improving their quality of life by seamlessly integrating multi-omics/bioinformatics/artificial intelligence with cell therapy.

Since its establishment, DISCOVERY TO CURE has remained quite low-profile, almost operating in "stealth mode" to quietly refine and develop its cutting-edge TIL (Tumor Infiltrating Lymphocyte) therapy platform. Its current "arsenal" includes neoantigen-driven TIL, single-cell multi-omics TIL scanning, and end-to-end CMC. The company has consistently adhered to a dual-driven strategy of independent research and external collaboration, establishing close partnerships with numerous top-tier research institution teams in both China and the United States.